A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
In brief
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Key facts
- Study ID
- NCT03157128
- Run by
- Eli Lilly and Company
- People needed
- 857
- Starts
- 2017-05-02
- Expected to finish
- 2027-02-01
- Last updated by the study team
- 2026-04-16
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope National Medical Center — Duarte, California, United States
- UCLA Medical Center — Los Angeles, California, United States
- Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
- Kaiser Permanente — Oakland, California, United States
- Irvine Medical Center — Orange, California, United States
- University of California - San Diego — San Diego, California, United States
- UCSF Medical Center at Mission Bay — San Francisco, California, United States
- Kaiser Permanente Medical Center — Walnut Creek, California, United States
- Sarah Cannon Research Institute at HealthOne — Denver, Colorado, United States
- Yale Cancer Center — New Haven, Connecticut, United States
- Mayo Clinic in Florida — Jacksonville, Florida, United States
- Memorial Hospital Pembroke — Pembroke, Florida, United States
- Emory University — Atlanta, Georgia, United States
- University of Chicago Medicine-Comprehensive Cancer Center — Chicago, Illinois, United States
- Ochsner Clinic Foundation — New Orleans, Louisiana, United States
- University of Maryland Medical Center — Baltimore, Maryland, United States
- Johns Hopkins University — Baltimore, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- University of Michigan — Ann Arbor, Michigan, United States
- START Midwest — Grand Rapids, Michigan, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Washington University Medical School — St Louis, Missouri, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- Mayo Clinic of Scottsdale — Scottsdale, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.